Current Models of Transcatheter Aortic Valves: Comparative Analysis of Design, Clinical Outcomes and Development Prospects
Objectives: Transcatheter aortic valve implantation (TAVI) has become the standard of care for severe aortic stenosis across all surgical risk categories. Continuous innovation in prosthesis technology necessitates a comprehensive and clinically oriented analysis of contemporary TAVI systems to guide device selection and understand evolving trends. This review aims to provide a practical, device-specific decision-making framework for TAVI prosthesis selection, synthesizing the latest evidence (2023–2025) to address the challenge of individualized choice in an era of device proliferation. We conducted a detailed review of current TAVI models from leading manufacturers (Medtronic, Abbott, Boston Scientific, Biotronik, etc.), examining their technical specifications, design innovations, and data from recent international clinical trials and registries. A comparative analysis was performed based on key parameters: delivery profile, resheathability/repositionability, sealing mechanisms, hemodynamic performance, and complication rates. Modern TAVI prostheses demonstrate significant advancements. Self-expanding nitinol frames offer superior adaptability and lower profiles (as low as 14 Fr). Innovations in sealing technology have drastically reduced the incidence of moderate-to-severe paravalvular leak (PVL) to below 2–3%. Supra-annular leaflet designs provide superior hemodynamics. Clinical outcomes show excellent 30-day mortality rates (1.1–2.0%) and durability estimates of 10–15 years. Variation exists between devices in rates of permanent pacemaker implantation and coronary access. The current generation of TAVI prostheses represents a mature technology offering high safety and efficacy. The key development vectors are focused on further device miniaturization, enhancing long-term durability, and expanding indications. This analysis provides a novel, clinically oriented comparison that moves beyond technical specifications to guide optimal device selection based on specific patient anatomy and clinical characteristics.
Authors
- Ravil Sharifulin (ORCID: https://orcid.org/0000-0002-8832-2447)
- Bashir Tsaroev (ORCID: https://orcid.org/0000-0001-9988-2653)
- Svetlana Tamkovich (ORCID: https://orcid.org/0000-0001-7774-943X)
- A.S. Zalesov (ORCID: https://orcid.org/0000-0002-3928-7374)
- Oleg V. Krestyaninov (ORCID: https://orcid.org/0000-0001-5214-8996)
- K. Kozyr (ORCID: https://orcid.org/0000-0002-7470-2158)
- A. B. Mochalova (ORCID: https://orcid.org/0000-0002-3337-2332)
- B. Alexander
Institutions
- Novosibirsk State Medical University (RU)
- Novosibirsk State University (RU)
- Institute of Chemical Biology and Fundamental Medicine (RU)
- Ministry of Health of the Russian Federation (RU)
- Siberian Branch of the Russian Academy of Sciences (RU)
- Meshalkin National Medical Research Center (RU)
Publication Details
- Journal
- Applied Sciences
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3390/app152211997
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Russian Science Foundation